Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYGR Voyager Therapeutics

Market Closed 04-10 16:00:00 EDT

3.74

-0.22

-5.56%

盘后3.76

+0.02+0.53%

19:44 EDT

High4.01	Low3.67	Vol787.50K
Open3.97	D1 Closing3.96	Amplitude8.46%
Mkt Cap222.90M	Tradable Cap176.97M	Total Shares59.60M
T/O2.95M	T/O Rate1.66%	Tradable Shares47.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYGR","market":"US","secType":"STK","nameCN":"Voyager Therapeutics","latestPrice":3.74,"timestamp":1775851200000,"preClose":3.96,"halted":0,"volume":787501,"hourTrading":{"tag":"盘后","latestPrice":3.7598,"preClose":3.74,"latestTime":"19:44 EDT","volume":370,"amount":1392.453,"timestamp":1775864697569,"change":0.0198,"changeRate":0.005294,"amplitude":0.005294},"delay":0,"changeRate":-0.05555555555555549,"floatShares":47318300,"shares":59599375,"eps":-2.039999,"marketStatus":"Market Closed","change":-0.22,"latestTime":"04-10 16:00:00 EDT","open":3.97,"high":4.005,"low":3.67,"amount":2954958.9023240004,"amplitude":0.084596,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.039999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":3.96,"preHourTrading":{"tag":"盘前","latestPrice":3.96,"preClose":3.96,"latestTime":"09:29 EDT","volume":1701,"amount":6815.9104019999995,"timestamp":1775827799909,"change":0,"changeRate":0,"amplitude":0.012626},"postHourTrading":{"tag":"盘后","latestPrice":3.7598,"preClose":3.74,"latestTime":"19:44 EDT","volume":370,"amount":1392.453,"timestamp":1775864697569,"change":0.0198,"changeRate":0.005294,"amplitude":0.005294},"volumeRatio":1.2535360757325547,"impliedVol":0.3194,"impliedVolPercentile":0.116},"requestUrl":"/m/hq/s/VYGR/wiki","defaultTab":"wiki","newsList":[{"id":"2626143361","title":"Voyager Therapeutics management to meet with Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626143361","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626143361?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:55","pubTimestamp":1775854557,"startTime":"0","endTime":"0","summary":"Meeting to be held on April 13 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BK4127","VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148585","title":"Voyager Therapeutics announces annual shareholder meeting agenda includes authorized share increase vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148585","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148585?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:23","pubTimestamp":1775852587,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics schedules 2026 annual shareholder meeting for June 9 in virtual format.Shareholders will vote on election of three Class II directors: James Geraghty, Steven Hyman, Alfred Sandrock.Agenda includes advisory vote on named executive officer compensation.Meeting will also seek ratification of Ernst & Young as independent auditor for fiscal 2026.Investors will vote on charter amendment to raise authorized shares to 245,000,000 from 125,000,000, including common stock to 240,000,000 from 120,000,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL4Ph9gw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624669368","title":"Top Executive at Voyager Therapeutics Makes Notable Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669368","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624669368?lang=en_us&edition=fundamental","pubTime":"2026-04-04 10:02","pubTimestamp":1775268123,"startTime":"0","endTime":"0","summary":"New insider activity at Voyager Therapeutics ( ($VYGR) ) has taken place on April 3, 2026. Voyager Therapeutics has seen insider activity as Presid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-at-voyager-therapeutics-makes-notable-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-at-voyager-therapeutics-makes-notable-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621033308","title":"Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621033308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621033308?lang=en_us&edition=fundamental","pubTime":"2026-03-24 07:35","pubTimestamp":1774308944,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Samantha Semenkow from Citi reiterated a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-early-stage-tau-program-optionality-drives-high-risk-high-upside-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-early-stage-tau-program-optionality-drives-high-risk-high-upside-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620847421","title":"Voyager Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620847421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620847421?lang=en_us&edition=fundamental","pubTime":"2026-03-18 01:41","pubTimestamp":1773769260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 13:41 ET (17:41 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620471120","title":"Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471120","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471120?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:45","pubTimestamp":1773765921,"startTime":"0","endTime":"0","summary":"Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, retaining the price target of $25.00. Patrick Trucchio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-differentiated-cns-platform-strategic-partnerships-and-2026-data-catalysts-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-differentiated-cns-platform-strategic-partnerships-and-2026-data-catalysts-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNS","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620712429","title":"Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620712429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620712429?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747015,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merit Medical Systems (MMSI – Research Report), Voya...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merit-medical-systems-mmsi-voyager-therapeutics-vygr-and-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merit-medical-systems-mmsi-voyager-therapeutics-vygr-and-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","BK4588","BK4139","LU0128526141.USD","VYGR","BK4585","XBI","BK4007","BK4599","XLV","LU1559883803.SGD","BK4581","HCSG","BK4198","LU0029874061.USD","MMSI","GPCR","BK4137","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618792003","title":"Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2618792003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618792003?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:45","pubTimestamp":1773254723,"startTime":"0","endTime":"0","summary":"Analyst Yun Zhong of Wedbush maintained a Buy rating on Voyager Therapeutics, with a price target of $8.00. Yun Zhong has given his Buy rating due ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-advancing-tau-targeted-gene-therapy-with-multiple-near-term-catalysts-and-attractive-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-advancing-tau-targeted-gene-therapy-with-multiple-near-term-catalysts-and-attractive-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618413249","title":"Guggenheim Remains a Buy on Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618413249?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:17","pubTimestamp":1773227827,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating on Voyager Therapeutics yesterday and set a price target of $22.00. The company’s s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618991384","title":"Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2618991384","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618991384?lang=en_us&edition=fundamental","pubTime":"2026-03-11 14:01","pubTimestamp":1773208912,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. (VYGR) has disclosed a new risk, in the Capital Markets category. Voyager Therapeutics Inc. faces heightened exposure to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-faces-rising-tariff-and-u-s-china-geopolitical-risks-as-biosecure-act-threatens-key-chinese-cdmo-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-faces-rising-tariff-and-u-s-china-geopolitical-risks-as-biosecure-act-threatens-key-chinese-cdmo-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618308739","title":"Voyager Therapeutics: Undervalued Neurology Pipeline With High‑Reward 2026 Catalysts Supports Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618308739","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618308739?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143726,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sumant Kulkarni from Canaccord Genuity m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-undervalued-neurology-pipeline-with-high‑reward-2026-catalysts-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-undervalued-neurology-pipeline-with-high‑reward-2026-catalysts-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618346089","title":"Voyager Therapeutics: 2026 Tau Data Catalysts and Gene Therapy Milestones Support Buy/High Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618346089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618346089?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:56","pubTimestamp":1773140187,"startTime":"0","endTime":"0","summary":"In a report released today, Samantha Semenkow from Citi maintained a Buy rating on Voyager Therapeutics, with a price target of $11.00. Samantha Se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-2026-tau-data-catalysts-and-gene-therapy-milestones-support-buy-high-risk-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-2026-tau-data-catalysts-and-gene-therapy-milestones-support-buy-high-risk-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618931926","title":"Voyager Therapeutics (VYGR) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618931926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618931926?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:35","pubTimestamp":1773138933,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target of $25.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618608425","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and West Pharmaceutical Services (WST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618608425?lang=en_us&edition=fundamental","pubTime":"2026-03-10 07:00","pubTimestamp":1773097240,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report) and We...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4585","XLV","BK4121","WST","BK4581","BK4139","IE00BYQQ9H92.USD","HCSG","BK4504","BK4588","XBI","IE00B64QTZ34.USD","LU0128526141.USD","LU0345774391.USD","LU0345774631.USD","BK4137","BK4567","IE00BFXG0V08.USD","LABU","LU0012050646.USD","VYGR","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618672798","title":"Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672798","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672798?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:55","pubTimestamp":1773089743,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryVoyager Therapeutics Inc VYGR.OQ reported a quarterly adjusted loss of 46 cents per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL8N3ZX2F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618209674","title":"Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618209674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618209674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:10","pubTimestamp":1773087045,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $15.34M, consensus $10.49M. “Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by thr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q4-eps-46c-consensus-51c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q4-eps-46c-consensus-51c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618367108","title":"Voyager Therapeutics Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618367108","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618367108?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086511,"startTime":"0","endTime":"0","summary":"Voyager reported Q4 collaboration revenue of USD 15.34 million, up 144%, driven mainly by higher revenue recognized under its Neurocrine agreement. Q4 net loss was USD 27.43 million, while R&D expenses were USD 35.95 million and G&A expenses were USD 9.32 million. For FY2025, collaboration revenue was USD 40.37 million, down 50% due mainly to higher collaboration revenue recognized in FY2024 tied to the Neurocrine and Novartis agreements, and net loss was USD 119.72 million. Voyager ended FY2025 with cash, cash equivalents and marketable securities of USD 201.69 million and said it expects its cash runway to extend into 2028. Management said 2026 priorities include first-in-human dosing of its tau-silencing gene therapy VY1706 in H2 2026 and tau PET imaging data from the VY7523 Alzheimer’s MAD trial in H2 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL9qYNDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","LU0109394709.USD","LU0823416689.USD","LU0889565916.HKD","LU2065171311.SGD","VYGR","LU0314104364.USD","LU2065169927.USD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","LU0154245756.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","LU2324357040.USD","BK4112","LU2065171402.SGD","SG9999014005.SGD","LU0320765992.SGD","BK4139","IE00BGHQF748.EUR","NBIX","SG9999014021.USD","LU0154245673.USD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618710366","title":"BRIEF-Voyager Therapeutics Q4 EPS USD -0.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2618710366","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618710366?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086505,"startTime":"0","endTime":"0","summary":"BRIEF-Voyager Therapeutics Q4 EPS USD -0.46\n\n\nMar 09 (Reuters) - Voyager Therapeutics Q4 basic EPS USD -0.47.\n\nQ4 net income USD -27.426 million\nQ4 collaboration revenue USD 15.336 million\nQ4 operating income USD -29.932 million\nQ4 pretax profit USD -27.417 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX4EAB82:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618671730","title":"Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671730?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUAFJ2LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618006671","title":"Voyager Therapeutics Inc: Ended 2025 With Cash Position of $202 Million, Expected to Maintain Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2618006671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618006671?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX4EAB82:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.voyagertherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0556},{"period":"1month","weight":-0.2289},{"period":"3month","weight":-0.0697},{"period":"6month","weight":-0.252},{"period":"1year","weight":0.2508},{"period":"ytd","weight":-0.0483}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.004281},{"month":2,"riseRate":0.545455,"avgChangeRate":0.057874},{"month":3,"riseRate":0.454545,"avgChangeRate":0.037898},{"month":4,"riseRate":0.454545,"avgChangeRate":0.014641},{"month":5,"riseRate":0.6,"avgChangeRate":0.041264},{"month":6,"riseRate":0.5,"avgChangeRate":0.010419},{"month":7,"riseRate":0.4,"avgChangeRate":-0.019026},{"month":8,"riseRate":0.6,"avgChangeRate":-0.020662},{"month":9,"riseRate":0.2,"avgChangeRate":0.071458},{"month":10,"riseRate":0.3,"avgChangeRate":-0.010359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.07862},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.036226}],"exchange":"NASDAQ","name":"Voyager Therapeutics","nameEN":"Voyager Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Voyager Therapeutics,VYGR,Voyager Therapeutics股票,Voyager Therapeutics股票老虎,Voyager Therapeutics股票老虎国际,Voyager Therapeutics行情,Voyager Therapeutics股票行情,Voyager Therapeutics股价,Voyager Therapeutics股市,Voyager Therapeutics股票价格,Voyager Therapeutics股票交易,Voyager Therapeutics股票购买,Voyager Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}